** Shares of gene therapy developer Sarepta Therapeutics SRPT.O up 2.1% to $63.21
** H.C. Wainwright raises SRPT's rating to "neutral" from "sell"
** Still expect Elevidys revenue to fall short in 2H25 — more so now after the recently reported patient death — expect a continued bolus demand effect from the June 2024 approval in older and non-ambulatory groups, brokerage says
** SRPT last month said a 16-year-old boy died from acute liver failure months after receiving U.S.-approved gene therapy Elevidys, for a rare muscular dystrophy
** Wainwright also believes there is a chance that the 2025 Elevidys ramp may sour faster—perhaps as soon as 2Q25— given the likelihood of increased hesitance by prescribers/patients
** The departure of U.S. FDA's top vaccine official, Peter Marks, casts uncertainty on the future of SRPT's development-stage portfolio - brokerage
** Up to last close, stock had fallen 49% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.